VentriPoint Diagnostics Ltd.VPT - TSX Venture
Shares issued: ~79.4 million
Fully diluted: ~99.6 million
*************************
Late last year VentriPoint raised some eyebrows with news that it was installing its heart measurement technology in a national reference hospital in Oslo, Norway.
Now comes news that leading Rikshospitalet cardiologist, Dr. Henrik Brun will be presenting a paper next week at a gathering of peers in Norway. Dr. Brun’s audience will be fellow pediatric cardiologists. The past three months of study utilizing VentriPoint’s VMS 3D technology to remodel the area of the right heart after valve replacement is the subject of the address.
Dr. Henry Brun noted, “It is time to tell other pediatric cardiologists about our first experience and what we hope to achieve; particularly for the follow-up of Tetralogy of Fallot (a heart disease often referred to as ‘blue-baby syndrome’) patients that we have studied using the VMS™ imaging process.”
VPT management anticipates that over the next two quarters there will be several such studies presented by cardiologists from leading reference hospitals in various countries.
Investors should note the importance of today’s news and future endorsements of the merits of the technology.
In simplistic fashion, VMS 3D technology is MRI “in a box” with a specific focus on the heart.
Click here to read the news release.
Now comes news that leading Rikshospitalet cardiologist, Dr. Henrik Brun will be presenting a paper next week at a gathering of peers in Norway. Dr. Brun’s audience will be fellow pediatric cardiologists. The past three months of study utilizing VentriPoint’s VMS 3D technology to remodel the area of the right heart after valve replacement is the subject of the address.
Dr. Henry Brun noted, “It is time to tell other pediatric cardiologists about our first experience and what we hope to achieve; particularly for the follow-up of Tetralogy of Fallot (a heart disease often referred to as ‘blue-baby syndrome’) patients that we have studied using the VMS™ imaging process.”
VPT management anticipates that over the next two quarters there will be several such studies presented by cardiologists from leading reference hospitals in various countries.
Investors should note the importance of today’s news and future endorsements of the merits of the technology.
In simplistic fashion, VMS 3D technology is MRI “in a box” with a specific focus on the heart.
Click here to read the news release.
0 comments:
Post a Comment